MOLECUBES

🌟 Happy New Year from the CUBES team! 🎉 As we welcome 2025, we want to express our heartfelt gratitude to our incredible community for your unwavering support and trust. You’ve been instrumental in our journey, and we are thrilled to share an exciting milestone with you! MOLECUBES is now officially part of Bruker Belgium! This new chapter marks a pivotal moment in our mission to innovate and advance preclinical molecular imaging. Together with Bruker, we’re ready to push the boundaries further—enhancing our capabilities, expanding our horizons, and delivering groundbreaking solutions to drive scientific discovery. Stay tuned for updates and breakthroughs as we embark on this exciting journey. We look forward to growing, innovating, and succeeding together with you in the year ahead. Here’s to a 2025 filled with progress, innovation, and shared success! Wishing you a prosperous and joyful New Year, The CUBES Team #HappyNewYear #PreclinicalImaging Bruker Preclinical Imaging Bruker BioSpin

From all of us from the CUBES team: Happy Holidays! 🎄 Here’s to a joyful holiday period filled with warmth, connection, and perhaps even a little inspiration for the year ahead. #Happyholidays

🎥 Missed our webinar? No worries! You can now rewatch it at your convenience!   Last week, we dove deep into quality control for preclinical imaging and shared key insights on the implementation of an effective and efficient quality control program for SPECT and PET systems in a preclinical imaging lab.   Whether you’re a seasoned professional or new to the field, this webinar is packed with valuable tips and practical takeaways.   👉 Rewatch the full webinar via the link below!   Have questions or feedback? We’d love to hear from you! Drop us a comment or reach out directly!   #QualityControl #PreclinicalImaging #Molecubes #Webinar

💡Application in the Spotlight!   Self-assembled porous metallacages are attractive supramolecular coordination complexes with various applications in medicine, including drug delivery, imaging, and the development of novel theranostic platforms. In vivo Positron Emission Tomography (PET) imaging can offer insights into the structural integrity of metallacages upon in vivo injection.   This study by CIC biomaGUNE (Cosialls et al.) explored the 18F-labelling of metallacages designed for drug delivery. The study also investigated the stability of the cages in the presence of cisplatin and their distribution in vivo through PET imaging and biodistribution studies in healthy mice.   The β-cube (PET) has been used to assess in vivo whole-body biodistribution of 18F-L1 and 18F-C1 cages non-invasively and quantitatively.   🔗 Read more about this paper via the link below!   #PreclinicalImaging #PreclinicalResearch #PET

🎬 We are going live!   Don't miss our exciting webinar "How to Implement an Efficient Quality Control Program in Preclinical Imaging: Insights from the Field"!   Join prof. Christian Vanhove and Dr. Milan Decuyper, together with our very own Dr. Kim Braeckman, and learn more about the implementation of an effective and efficient quality control program for SPECT and PET systems in a preclinical imaging lab.   Still wanting to join? Register now via the link below! See you there!   #QualityControl #Webinar #CUBEFLOW #ShiftingStandards Bruker Preclinical Imaging Bruker BioSpin

📍 We're attending the 6th annual #Targeted #Radiopharmaceuticals Summit in Amsterdam, on December 3-5! 🇳🇱 Our Market Development Manager, Sam De Decker, is looking forward to connecting with researchers and industry professionals passionate about advancing their preclinical research with #PET, #SPECT, and #CT imaging. 🤝 Catch up with Sam to discuss your research and discover how our CUBES can help you achieve your imaging goals faster and more efficiently. 💡 Curious about the importance of imaging in #theranostics research? Check out our whitepaper, "𝗧𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵" - Link in first comment 👇 https://lnkd.in/d6pfRuPX #PreclinicalImaging #NuclearImaging Hanson Wade Bruker Preclinical Imaging Bruker BioSpin

⭐️ Last day to register for our upcoming webinar on "How to Implement an Efficient Quality Control Program in Preclinical Imaging: Insights from the Field"! The webinar will take place on December 4th, 4 PM CET.   Join prof. Christian Vanhove and Dr. Milan Decuyper, together with our very own Dr. Kim Braeckman, to learn more about the implementation of an effective and efficient quality control program for SPECT and PET systems in a preclinical imaging lab. 🔗 Register now via the link below!   #QualityControl #Webinar #CUBEFLOW #ShiftingStandards Bruker Preclinical Imaging Bruker BioSpin

🍁 Happy Thanksgiving to our American colleagues and partners!   This Thanksgiving, we extend our heartfelt gratitude to all our American friends, especially our exceptional sales team members, Nas Imus M.S. and Scott D. Ireland. Your dedication drives innovation and excellence every day. We wish you and your loved ones a joyful and peaceful holiday! #Thanksgiving #Gratitude

💡 Don't forget to register for our upcoming webinar on "How to Implement an Efficient Quality Control Program in Preclinical Imaging: Insights from the Field"! The webinar will take place on December 4th, 4 PM CET.   Join Prof. Christian Vanhove, Dr. Milan Decuyper, and our very own Dr. Kim Braeckman to learn more about implementing an effective and efficient quality control program for SPECT and PET systems in a preclinical imaging lab.   🔗 Register now via the link below!   #QualityControl #Webinar #CUBEFLOW #ShiftingStandards Bruker Preclinical Imaging Bruker BioSpin

November is #Movember, an annual event to raise awareness of men's health issues, such as prostate cancer, testicular cancer, and men's suicide. In this post, we would like to highlight the groundbreaking research of one of our customers, whose work is making significant strides in the fight against prostate cancer.   The study of Bernabeau et al., from the Division of Radiopharmaceutical Chemistry, University Hospital Basel, aimed to assess the feasibility of 61Cu–PSMA–targeted tracers in terms of performance, clinical relevance, ease of production, and accessibility.   In this study, the β-CUBE scanner aided in providing high-resolution imaging that enabled the detailed preclinical evaluation of tracer distribution and tumor uptake. After injection, dynamic PET scans (0–1 h) were acquired after intravenous administration of 61Cu-labeled tracers, 68Ga-labeled tracers, and [18F]PSMA-1007. In addition, static scans at four hours after injection were acquired for the 61Cu-labeled tracers and [18F]PSMA-1007.   Overall, the findings of this study serve as a foundation for future clinical development of 61Cu-labeled tracers and suggest opportunities for developing other 61Cu-labeled tracers for a range of clinically valuable targets.   Read more about this paper via the link below!   #ProstaceCancer #PreclinicalImaging #PET